Literature DB >> 19754478

The effects of antenatal corticosteroids and surfactant replacement on neonatal respiratory distress syndrome.

Suada Heljić1, Hajrija Maksić, Ismeta Kalkan, Belma Krdalić.   

Abstract

The goal of this study was to determine the effects of antenatal corticosteroids and surfactant replacement on the severity and frequency of Respiratory Distress Syndrome (RDS) in a cohort of premature infants born in Sarajevo, Bosnia and Herzegovina, from 2005 to 2007. The cohort consisted of 172 premature neonates with estimated gestational age between 26 and 34 weeks. Babies with IUGR, babies of diabetic mothers and babies with major congenital defects were excluded. Out of 172 neonates, 80 were treated antenatally with corticosteroids (single course of dexamethasone) and 92/172 were not. There was no statistical difference (p>0,5) in average gestational age (31,2 vs. 31,0 GW) and male/female ratio between investigated groups; there were significantly more male patients (p<0,05) in both groups. Frequency of RDS was significantly lower in the corticosteroid group (24/80) in relation to the control group (54/92) (p<0,001). Severe RDS was significantly (p<0,01) more frequent in the control group 34/53 (62,96%) then in the corticosteroid group 6/24 (25,0%). Bovine surfactant (Survanta) was given as a rescue therapy to 78 babies with clinical and radiological signs of RDS who required FiO2>0,40 and mechanical ventilation. Early surfactant administration within six hours after birth appeared to be effective at reducing mortality then later surfactant administration (p<0,005). In the group of babies requiring FiO2> or =0,6 at the time of surfactant replacement, the mortality rate was significantly higher (p<0,05). In conclusion, we confirm the efficacy of antenatal corticosteroid treatment and early surfactant treatment in a cohort of premature infants born in Sarajevo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19754478      PMCID: PMC5632507          DOI: 10.17305/bjbms.2009.2811

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  16 in total

1.  Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants.

Authors:  O Baud; L Foix-L'Helias; M Kaminski; F Audibert; P H Jarreau; E Papiernik; C Huon; J Lepercq; M Dehan; T Lacaze-Masmonteil
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

2.  A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.

Authors:  G C Liggins; R N Howie
Journal:  Pediatrics       Date:  1972-10       Impact factor: 7.124

3.  Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial.

Authors:  Stuart R Dalziel; Natalie K Walker; Varsha Parag; Colin Mantell; Harold H Rea; Anthony Rodgers; Jane E Harding
Journal:  Lancet       Date:  2005 May 28-Jun 3       Impact factor: 79.321

4.  Surfactant replacement therapy: prophylaxis or treatment?

Authors:  M S Dunn
Journal:  Pediatrics       Date:  1993-07       Impact factor: 7.124

Review 5.  Prophylactic corticosteroids for preterm birth.

Authors:  P Crowley
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 6.  Glucocorticoid use in patients with preterm premature rupture of the fetal membranes.

Authors:  H M Imseis; J D Iams
Journal:  Semin Perinatol       Date:  1996-10       Impact factor: 3.300

7.  Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity.

Authors:  Arsenio Spinillo; Franco Viazzo; Rossella Colleoni; Alberto Chiara; Rosa Maria Cerbo; Elisa Fazzi
Journal:  Am J Obstet Gynecol       Date:  2004-07       Impact factor: 8.661

Review 8.  Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes.

Authors: 
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

9.  Partial or complete antenatal steroids treatment and neonatal outcome in extremely low birth weight infants < or =1000 g: is there a dose-dependent effect?

Authors:  Walid A Salhab; Linda S Hynan; Jeffrey M Perlman
Journal:  J Perinatol       Date:  2003-12       Impact factor: 2.521

10.  Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.

Authors:  C P Speer; O Gefeller; P Groneck; E Laufkötter; C Roll; L Hanssler; K Harms; E Herting; H Boenisch; J Windeler
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-01       Impact factor: 5.747

View more
  4 in total

1.  Intra-amniotic administration of exogenous pulmonary surfactant for improving in lung maturity of fetal rabbits with intrauterine infection caused by premature rupture of membranes.

Authors:  Jing Liu; Jing Wu; Na Yang; ZhiChun Feng
Journal:  Bosn J Basic Med Sci       Date:  2011-05       Impact factor: 3.363

Review 2.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

3.  Oxidative stress markers in neonatal respiratory distress syndrome: advanced oxidation protein products and 8-hydroxy-2-deoxyguanosine in relation to disease severity.

Authors:  Zeinab A Elkabany; Rania A El-Farrash; Dina M Shinkar; Eman A Ismail; Ahmed S Nada; Ahmed S Farag; Medhat A Elsayed; Dina H Salama; Eman L Macken; Saleh A Gaballah
Journal:  Pediatr Res       Date:  2019-06-19       Impact factor: 3.756

Review 4.  Y It Matters-Sex Differences in Fetal Lung Development.

Authors:  Mandy Laube; Ulrich H Thome
Journal:  Biomolecules       Date:  2022-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.